NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
Clinical Trials
10 trialsNCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT02589860 2022-01-10
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Indiana University
Withdrawn
NCT03704597 2018-10-15
Cryotherapy Against Oral Mucositis After High-dose Melphalan
Sahlgrenska University Hospital
Phase NA Unknown
NCT01653106 2017-06-27
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT01066624 2015-07-23
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
The University of Texas Health Science Center at San Antonio
Phase NA Completed
NCT00070616 2014-10-24
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Swedish Orphan Biovitrum
Phase 1 Completed
NCT00482846 2014-04-15
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT01402687 2013-07-16
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
Dana-Farber Cancer Institute
Completed
NCT00602147 2013-03-14
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Vanderbilt-Ingram Cancer Center
Terminated